Gaining the Upper Hand on Pulmonary Drug Delivery

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Drug Delivery

Background:

• Asthma, COPD, and Cystic Fibrosis are chronic lung diseases marked by inflammation and excess mucus.
• Excess mucus impairs lung function and increases susceptibility to bacterial infections.
• Current treatments face challenges in efficacy and side effects.

Purpose of the Study:

• To review current and emerging therapeutic options for chronic respiratory diseases.
• To discuss the challenges associated with drug delivery for these conditions.
• To highlight considerations for developing novel therapies.

Main Methods:

• Literature review of existing and developmental treatments for asthma, COPD, and CF.
• Analysis of drug delivery mechanisms and barriers in chronic lung diseases.
• Discussion of pharmacokinetic and pharmacodynamic considerations for inhaled and oral therapies.

Main Results:

• Oral medications offer ease of administration but carry risks of systemic side effects.
• Inhaled therapies face challenges including mucus barriers, enzymatic degradation, and rapid systemic absorption.
• Effective drug delivery is crucial for improving treatment outcomes in chronic respiratory diseases.

Conclusions:

• Developing effective treatments for asthma, COPD, and CF requires overcoming significant drug delivery hurdles.
• Optimizing inhaled drug formulations and delivery systems is essential.
• Further research is needed to enhance therapeutic efficacy and minimize adverse effects.